News 2016

PITTSBURGH, Dec. 13, 2016 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, today announced the initiation of U.S. clinical testing of CT1812, its proprietary first-in-class, orally available small molecule therapeutic being developed for the treatment of Alzheimer’s …

Cognition Therapeutics initiates US clinical testing of CT1812, a novel strong molecule for the potential treatment of Alzheimer’s disease Read More »

PITTSBURGH, Dec. 5, 2016 /PRNewswire/ — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, today announced that its poster focused on CT1812 safety data, its proprietary first-in-class, orally available small molecule in development for the treatment of Alzheimer’s disease, has been …

Cognition Therapeutics to Highlight CT1812 Safety Data at the 9th Clinical Trials on Alzheimer’s Disease (CTAD) Meeting Read More »

PITTSBURGH, Nov. 30, 2016 /PRNewswire/ — Susan Catalano, Ph.D., founder and CSO of Cognition Therapeutics, Inc., (CogRx) a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, chaired the Nanosymposium titled “sigma-2/PGRMC1 Receptor Function in Disease and Therapeutics” at the recent Society for …

Society for Neuroscience 2016 Nanosymposium Explores Potential of “Sigma-2/PGRMC1 Receptor Function in Disease and Therapeutics” Read More »

PITTSBURGH, Nov. 23, 2016 /PRNewswire/ — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, today provided its comments and perspective on the Phase 3 clinical trial data of Eli Lilly’s Alzheimer’s disease medicine, solanezumab. “These results, while disappointing …

CogRx Sees Lilly Solanezumab Results as Support for its Unique Mechanism for Treatment of Alzheimer’s Disease Read More »

— The first small molecule drug candidate showing ability to restore memory to normal in Alzheimer’s disease models — PITTSBURGH, Nov. 11, 2016 /PRNewswire/ — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, announced today that the first Alzheimer’s …

Cognition Therapeutics Announces Dosing of First Alzheimer’s Patient in Phase 1b Trial of CT1812 Read More »

PITTSBURGH, Oct. 28, 2016 /PRNewswire/ — Cognition Therapeutics, Inc., a clinical stage neuroscience therapeutics company, announced today that Kenneth I. Moch has been appointed President and Chief Executive Officer of the company. Mr. Moch will also join the company’s Board of Directors. Mr. Moch brings to Cognition more than 25 years of experience in creating, …

Alzheimer’s Drug Development Company Cognition Therapeutics appoints Kenneth I. Moch President & CEO Read More »

PITTSBURGH, Sept. 29, 2016 /PRNewswire/ — Cognition Therapeutics Inc. (CogRx), a privately held, clinical stage pharmaceutical company focused on discovering and developing disease-modifying therapies for neurodegenerative diseases, announced today that, aided by a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF), it will use its validated discovery platform to simultaneously discover drug …

Cognition Therapeutics (CogRx) Receives Michael J. Fox Foundation Grant to Study Inhibitors of Alpha-synuclein Oligomers for the Treatment of Parkinson’s Disease Read More »